Roquefort Therapeutics PLC
LSE:ROQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (4.5), the stock would be worth GBX-5.05 (167% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -6.7 | GBX7.5 |
0%
|
| Industry Average | 4.5 | GBX-5.05 |
-167%
|
| Country Average | 0.2 | GBX-0.23 |
-103%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
R
|
Roquefort Therapeutics PLC
LSE:ROQ
|
31.9m GBP | -6.7 | -1.4 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
285.6B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
100.2B ZAR | 15.5 | 10.4 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.9B USD | -88 198.6 | 38 368.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
59.7B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.4B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.4B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.5B USD | 45.4 | -3 256.9 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
29.7B ZAR | 4.9 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.2 |
| 70th Percentile | 0.4 |
| Max | 901.8 |
Other Multiples
Roquefort Therapeutics PLC
Glance View
Roquefort Therapeutics plc operates as an investment company. The firm is developing products through the pre-clinical phase. The firm operates through its subsidiary Lyramid Pty Ltd (Lyramid). Lyramid is a pre-clinical biotechnology company focused on developing first-in-class Midkine inhibiting ribonucleic acid (RNA) therapeutic drugs for the treatment of cancer, chronic inflammatory, and autoimmune disorders, as well as lung diseases such as COVID-19. Lyramid has identified the therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid also intends to develop its oligonucleotide, and potentially antibody, drugs through preclinical and early clinical development.
